SG11202010136UA - Treatments - Google Patents

Treatments

Info

Publication number
SG11202010136UA
SG11202010136UA SG11202010136UA SG11202010136UA SG11202010136UA SG 11202010136U A SG11202010136U A SG 11202010136UA SG 11202010136U A SG11202010136U A SG 11202010136UA SG 11202010136U A SG11202010136U A SG 11202010136UA SG 11202010136U A SG11202010136U A SG 11202010136UA
Authority
SG
Singapore
Prior art keywords
treatments
Prior art date
Application number
SG11202010136UA
Inventor
Ian Hampson
Lynne Hampson
Original Assignee
Douglas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Douglas Pharmaceuticals Ltd filed Critical Douglas Pharmaceuticals Ltd
Publication of SG11202010136UA publication Critical patent/SG11202010136UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0031Rectum, anus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11202010136UA 2018-05-24 2019-05-23 Treatments SG11202010136UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1808563.9A GB201808563D0 (en) 2018-05-24 2018-05-24 Treatments
PCT/IB2019/054293 WO2019224780A1 (en) 2018-05-24 2019-05-23 Treatments

Publications (1)

Publication Number Publication Date
SG11202010136UA true SG11202010136UA (en) 2020-11-27

Family

ID=62812513

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010136UA SG11202010136UA (en) 2018-05-24 2019-05-23 Treatments

Country Status (12)

Country Link
US (1) US20210213016A1 (en)
EP (1) EP3801508A1 (en)
JP (1) JP2021525263A (en)
CN (1) CN112165941A (en)
AU (1) AU2019274813A1 (en)
BR (1) BR112020023972A2 (en)
CA (1) CA3100428A1 (en)
GB (1) GB201808563D0 (en)
MX (1) MX2020012622A (en)
SG (1) SG11202010136UA (en)
WO (1) WO2019224780A1 (en)
ZA (1) ZA202006321B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201808564D0 (en) 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Treatments

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129208A1 (en) * 2002-01-07 2003-07-10 Alberts David S. Topical application of alpha-DFMO and anti-inflammatory drug for treatment of actinic keratoses
GB201115635D0 (en) * 2011-09-09 2011-10-26 Univ Liverpool Compositions of lopinavir and ritonavir
AU2014338707B2 (en) * 2013-10-23 2020-06-04 The University Of Manchester Treatment of cancer and benign proliferative disorders

Also Published As

Publication number Publication date
WO2019224780A1 (en) 2019-11-28
GB201808563D0 (en) 2018-07-11
AU2019274813A1 (en) 2020-12-10
CA3100428A1 (en) 2019-11-28
MX2020012622A (en) 2021-01-29
US20210213016A1 (en) 2021-07-15
ZA202006321B (en) 2022-01-26
CN112165941A (en) 2021-01-01
EP3801508A1 (en) 2021-04-14
JP2021525263A (en) 2021-09-24
BR112020023972A2 (en) 2021-02-23

Similar Documents

Publication Publication Date Title
IL277336A (en) Combination therapy
GB201804255D0 (en) Macrophage-based therapy
GB201800274D0 (en) Novel treatments
GB201813876D0 (en) Treatment
GB201819853D0 (en) Therapy
GB201820660D0 (en) Cancer treatments
IL281792A (en) Treatment methods
IL280968A (en) Combination therapy
IL279908A (en) Combination therapy
GB201800546D0 (en) Treatment
GB201701315D0 (en) Novel treatments
GB201808564D0 (en) Treatments
IL281839A (en) Treatment methods
ZA202006321B (en) Treatments
IL280729A (en) Combination therapy
GB201820215D0 (en) Treatments etc
IL288526A (en) Thiarabine- and thiarabine prodrug-based treatments
GB201801982D0 (en) Novel treatments
GB201917908D0 (en) Novel treatments
GB201913636D0 (en) Novel treatments
GB201814905D0 (en) Treatment
GB201904714D0 (en) Novel treatments
IL262221A (en) Treat ments forcahcers etc
GB201820895D0 (en) Therapy
GB201817385D0 (en) Therapy